Allogene Therapeutics (ALLO) Free Cash Flow (2018 - 2026)

Allogene Therapeutics has disclosed Free Cash Flow across 9 years of filings, most recently posting -$12.9 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$12.9 million, up 75.59% year-over-year; the trailing twelve-month figure through Mar 2026 was -$109.3 million (up 44.78% YoY), and the FY2025 annual result was -$149.4 million, up 25.69% from the prior year.
• Free Cash Flow came in at -$12.9 million for Q1 2026 at Allogene Therapeutics, up from -$27.3 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$12.9 million in Q1 2026 to a low of -$70.1 million in Q1 2022.
• The 5-year median for Free Cash Flow is -$52.9 million (2025), against an average of -$48.5 million.
• Across the five-year window, Free Cash Flow sank 124.09% in 2022 and soared 75.59% in 2026, its largest moves.
• Allogene Therapeutics' Free Cash Flow stood at -$59.3 million in 2022, then rose by 9.09% to -$53.9 million in 2023, then jumped by 31.42% to -$37.0 million in 2024, then gained by 26.07% to -$27.3 million in 2025, then surged by 52.7% to -$12.9 million in 2026.
• The last three Free Cash Flow figures came in at -$12.9 million (Q1 2026), -$27.3 million (Q4 2025), and -$29.9 million (Q3 2025), per Business Quant data.